University of Chicago Extends Collaboration with AbbVie to Advance Clinical Research and Patient Outcomes in Oncology

You are a text condensation assistant.

Rules:
1. If the text length is already <= 8000 characters, return it unchanged.
2. If the text is longer, shorten it to <= 8000 characters while preserving its essential meaning, intent, and key information.
3. Remove secondary details, repetitions, and minor nuances, but keep the core message accurate.
4. Your output MUST NOT exceed 8000 characters.
5. Return ONLY the final condensed text. No explanations or comments.

TEXT:
The University of Chicago Medicine has extended its collaboration with AbbVie through 2027 to support cancer research and clinical trials. The extension builds on a partnership that began in 2016 and focuses on translational and clinical research to improve and accelerate outcomes for patients with cancer.

Despite advances in treatment, cancer remains a leading cause of death worldwide, underscoring the need for continued innovation in therapies and clinical trial methods. The extended agreement aims to address these challenges through joint research and faster translation of discoveries to patient care.

“The AbbVie-UChicago Medicine collaboration has created valuable opportunities for deep and meaningful scientific discussion and the development of clinical trials for cancer treatment,” said Kunle Odunsi, MD, PhD, Director of the University of Chicago Medicine Comprehensive Cancer Center and AbbVie Foundation Distinguished Professor. “This partnership is an exceptional model of industry and academia working together with a patient-centered focus. Our ambition is that this clinical and translational collaboration continues to positively impact public health and advance cancer treatment.”

The extension will further accelerate oncology research and streamline clinical trial operations to enhance connectivity between clinicians and researchers at both organizations. The collaboration will benefit from additional infrastructure as UChicago Medicine prepares to open the AbbVie Foundation Cancer Pavilion in 2027, billed as Illinois’ first freestanding cancer center with dedicated clinical trial spaces and advanced research facilities.

“Our partnership with the University of Chicago is driven by our shared dedication to advancing cancer research and clinical innovation,” said Andrew Souers, PhD, vice president, oncology discovery research at AbbVie. “While we have made significant progress in cancer research, there is more to accomplish together. We look forward to deepening our long-standing collaboration to continue delivering meaningful, lasting impact for people living with cancer.”